Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Alpha-lactalbumin + symbiotic** is a combination product used primarily in infant formula and dietary supplements. This formulation typically includes **alpha-lactalbumin**, the major whey protein in human milk, and a **symbiotic** component (a mixture of probiotics and prebiotics). - **Alpha-lactalbumin** provides a high-quality source of essential amino acids—particularly rich in tryptophan—and may exert immunomodulatory, prebiotic, and antimicrobial effects. It supports infant growth and development and is used to improve the aminogram and reduce the total protein content of formulas, aiming to mimic human milk protein composition. - **Symbiotic supplementation** introduces both beneficial bacteria (probiotics, such as *Lactobacillus rhamnosus* and *Bifidobacterium* spp.) and prebiotic substrates (non-digestible ingredients that stimulate the growth of beneficial bacteria). This combination has been associated with improved gastrointestinal tolerance, positive modulation of the gut microbiota, increased fecal IgA, possible reduction in atopic dermatitis, and other gut-immune health benefits in infants[1][2]. - Mechanistically, the **probiotics** contribute to colonization resistance, immune modulation, and competitive exclusion of pathogens, while **prebiotics** provide fermentable substrates, resulting in increased production of short-chain fatty acids and support for the beneficial microbiome. - This combination is investigated mainly for its potential to support infant nutrition and wellbeing, reduce gastrointestinal symptoms, improve tolerance, and may have roles in reducing atopic dermatitis[1]. - Products may differ in the specific symbiotic components used (strain composition and prebiotic source).[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-lactalbumin + symbiotic.